Prescient Therapeutics LimitedASX: PTX

First Patient Dosed on Phase 1b/2 AML Trial

Dec 14, 2016 at 3:47 AM UTC · Issued by Prescient Therapeutics Limited

Prescient Therapeutics Ltd has released a press release.

View Attachment